Insmed reported $1.05B in Assets for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
DBV Technologies DBVT:US 284.98M 167.4M
Acelrx Pharmaceuticals ACRX:US $ 56.13M 15.84M
Alimera Sciences ALIM:US $ 47.57M 2.36M
Biomarin Pharmaceutical BMRN:US $ 6145.84M 83.13M
Cytokinetics CYTK:US $ 771.72M 84.54M
Dynavax Technologies DVAX:US $ 1023M 14.02M
Gilead Sciences GILD:US $ 62870M 210M
Heron Therapeutics HRTX:US $ 243.96M 29.76M
Insmed INSM:US $ 1.05B 99.96M
Mirati Therapeutics MRTX:US $ 1279.79M 141.51M
Novartis NVS:US $ 122910M 2308M
Ophthotech OPHT:US $ 319.76M 32.95M
Regeneron Pharmaceuticals REGN:US $ 27205.8M 857.1M
Sarepta Therapeutics SRPT:US $ 2996.85M 59.3M
Seattle Genetics SGEN:US $ 3630.34M 13.65M
Ultragenyx Pharmaceutical RARE:US $ 1320.63M 63.4M
Vertex Pharmaceuticals VRTX:US $ 15582.2M 1326.1M